Treatment of multiple sclerosis (Q57912414)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7905103%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

review article

1 reference

title

Treatment of multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7905103%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7905103%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

author name string

G.C Ebers

series ordinal

1

0 references

language of work or name

English

0 references

publication date

1 January 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7905103%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7905103%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

volume

343

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7905103%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

issue

8892

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7905103%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

page(s)

275-279

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7905103%20AND%20SRC:MED&resulttype=core&format=json

Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity

28 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

The pathological evolution of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Intravenous methylprednisolone for multiple sclerosis in relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Effect of total lymphoid irradiation in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Randomised double blind controlled trial of cyclosporin in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Overview of azathioprine treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

Myelin antigen reactive T cells in cerebrovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2991119-3

7 January 2021

10.1016/S0140-6736(94)91119-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7905103%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference